New hope for liver cancer patients with cirrhosis: immunotherapy combo under study

This study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) in 32 people with advanced liver cancer who also have moderate cirrhosis (Child-Pugh B). The main goal is to see if the treatment is safe and tolerable, and to measure how well it shrinks tumors. The research focuses on a group often left out of trials, including racial and ethnic minorities, to gather much-needed data.